Covalon Technologies (CVE:COV) Reaches New 52-Week High – Still a Buy?

Covalon Technologies Ltd. (CVE:COV) shares reached a new 52-week high on Friday . The stock traded as high as C$3.58 and last traded at C$3.57, with a volume of 28386 shares trading hands. The stock had previously closed at C$3.44.

Covalon Technologies Stock Up 4.7 %

The company has a quick ratio of 6.45, a current ratio of 5.24 and a debt-to-equity ratio of 4.98. The company has a market capitalization of C$98.64 million, a P/E ratio of -86.00 and a beta of 0.64. The firm has a 50-day moving average price of C$3.24 and a two-hundred day moving average price of C$2.39.

Covalon Technologies (CVE:COV) last issued its earnings results on Wednesday, August 21st. The company reported C$0.06 EPS for the quarter. The business had revenue of C$9.22 million during the quarter. Covalon Technologies had a negative return on equity of 3.85% and a negative net margin of 2.82%. Equities research analysts anticipate that Covalon Technologies Ltd. will post 0.3 EPS for the current fiscal year.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.